SP 600125 - NSC 75890

Based on 337 publications in PubMed 10 10 337

Axon 2519

CAS [129-56-6]

MW 220.23

  • Purity: 98%
  • Soluble in DMSO

SP 600125


Reversible ATP-competitive JNK inhibitor (IC50 values 40 nM, 40 nM, and 90 nM for JNK1, JNK2 and JNK3, respectively) with >20-fold selectivity vs. a range of kinases and enzymes tested. SP600125 caused G2/M cell cycle arrest and elevation of cyclin B1 and p27(kip), thereby inhibiting cell proliferation and increasing apoptosis in multiple cell lines. Moreover, SP600125 dose dependently inhibits phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-γ, TNF-α, and prevents activation and differentiation of primary human CD4 cell cultures; SP600125 has proven to be a useful tool for isolation, generation, derivatization and stabilization of naive human pluripotent stem cells in so called NHSM conditions developed at the Weizmann Institute of Science.

*Promotion: SP 600125 is also part of Inhibitor Set(s):

Axon 5010

KEYWORDS: SP 600125 | supplier | JNK inhibitor | NSC 75890 | SP600125 | NSC75890 | CAS [129-56-6] | [67072-00-8] | MAPK | c-Jun | kinase | Inhibitor | ATP competitive | G2/M | arrest | proliferation | apoptosis | NHSM | pluripotent | stem cell | hPSC | derivatisation | Weizmann Institute

Size Unit Price Stock
10 mg €70.00 In Stock
50 mg €210.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...